Azitra, Inc. (AZTR) stock
AZTRNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.61−0.06 (-8.99%)
Close on Nov 13, 2026Market cap $3.69MP/E –Yield –
Azitra EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Azitra's EPS for the twelve months ending Sep 30, 2023 was -$20018.37. For fiscal 2025 it was -$22.50.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$22.50 | – |
| FY2024 | Dec 31, 2024 | -$157.00 | – |
| FY2023 | Dec 31, 2023 | -$3665.33 | – |
| FY2022 | Dec 31, 2022 | -$25480.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.29 | – |
| Q2 FY2026 | Jun 30, 2026 | -$1.70 | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.50 | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.71 | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.80 | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.50 | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.40 | – |
| Q2 FY2024 | Jun 30, 2024 | -$182.67 | – |
| Q1 FY2024 | Mar 31, 2024 | -$288.00 | – |
| Q3 FY2023 | Sep 30, 2023 | -$321.33 | – |
| Q2 FY2023 | Jun 30, 2023 | -$4722.00 | – |
| Q1 FY2023 | Mar 31, 2023 | -$6000.00 | – |
| Q4 FY2022 | Dec 31, 2022 | -$8975.04 | – |
| Q3 FY2022 | Sep 30, 2022 | -$5900.00 | – |
| Q2 FY2022 | Jun 30, 2022 | -$4900.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?